JeanMarie Guenot – Pharmaceutical Expert Committed To Fighting Cancer

 

JeanMarie’s Background

 

JeanMarie Guenot is the CEO and president of Amphivena Therapeutics, a firm based in San Francisco, California. The company deals with products in pharmaceutical and bio-tech sectors. She boasts of over two decades in the industry dealing with cardiovascular conditions, neurology, and oncology and so on. She holds an MBA from the University of Pennsylvania, Wharton School, and a Ph.D. from the University of California, San Francisco. Her broad knowledge in medicine, particularly quantum mechanical methods, have made her hold numerous prominent positions in an array of firms.

 

Career

 

JeanMarie Guenot has served in different capacities at various companies in the pharmaceutical industries. After attaining her doctorate, she got her first job at Hoffman – La Roche as the chief scientist. Later, she moved to Atlas Venture. At Atlas, she oversaw capital investments and assisted in the start-up of biotechnology enterprises. She left Atlas for PDL BioPharma where she was promoted to vice president. In 2009, she inaugurated SKS Ocular LLC, a pharmaceutical firm based in San Diego, California.

Amphivena Therapeutics Achieves Development Milestones Under Agreement With Janssen

During her time at PDL, she masterminded acquisitions and mergers, as well as recording high-profit margins. One of the significant mergers was between the firm and Biogen Idec., which saw the two companies collaborate in development of products. The merger, worth $800 million, involved stage 2 cancer patients and three autoimmune drug candidates.

 

Amphivena Therapeutics

 

Under the excellent leadership of JeanMarie Guenot, the company has developed several drugs that combat blood cancers. They aim to alleviate the conditions by restoring cellular balance. The firm believes if the blood forming process is stabilized, the body’s defence mechanism will fend off tumours and their causing agents.

 

Recently, the Food and Drug Administration (FDA) authorized the use of trial drug on Phase 1 cancer patients. The medication aims to lessen the effects of acute myeloid leukaemia.

 

Amphivena therapeutics was founded in 2013 and is based in San Francisco, California. The institution aims to avail the best oncology solutions to patients suffering from haematological cancers.

Read more about Jeanmarie Guenot’s life saving worth with Takeda on their website: https://www.takeda.com/news/2017/20170111_7659.html